In 2024, Ruscitti et al. detailed significant advancements and emerging theories regarding Still’s disease in their comprehensive review titled Recent advances and evolving concepts in Still’s disease, published in Nature Reviews Rheumatology. The article meticulously discusses clinical implications and future directions in the management of this complex condition. 20, 116–132 (2024).
De Matteis et al. argue that systemic juvenile idiopathic arthritis and adult-onset Still’s disease represent the same pathological entity, supported by systematic reviews and meta-analyses. Their findings are crucial in shaping the 2023 EULAR/PReS recommendations for the diagnosis and management of Still’s disease, providing compelling evidence for clinical practitioners. Ann. Rheum. Dis. (2024).
Fautrel et al.’s 2024 publication outlines critical EULAR/PReS guidelines for diagnosing and managing Still’s disease, which encompasses both systemic juvenile idiopathic arthritis and adult-onset Still’s disease. This authoritative guidance is essential for healthcare professionals dealing with these interrelated inflammatory conditions. Ann. Rheum. Dis. (2024).
In the 2023 study conducted by Vitale et al., the continuum of Still’s disease from childhood to old age is explored, drawing on data from the international AIDA Network’s Still’s disease registry. This research highlights the evolving clinical picture of Still’s disease over the lifespan and underscores the importance of continuous assessment and personalized management strategies. RMD Open 9, e003578 (2023).
Bindoli et al. in their 2024 review analyze recent findings in the understanding of adult-onset Still’s disease (AOSD), encompassing its pathophysiology, genetic predispositions, and advancing treatment modalities. Their research synthesizes the latest knowledge in the field and proposes future directions for therapeutic innovations. Drugs 84, 257–274 (2024).
Shen et al. emphasize the significance of personalized precision treatment for Still’s disease, advocating for approaches based on molecular characteristics and the progression of the disease. This innovative perspective potentially paves the way for tailored interventions, improving patient outcomes in the management of this complex rheumatological condition. Lancet Rheumatol. (2024).
What are the latest recommendations for the diagnosis and management of Still’s disease, including both systemic juvenile idiopathic arthritis and adult-onset Still’s disease?
Here are the formatted references based on the information you provided:
1. Fautrel, B. EULAR/PReS recommendations for the diagnosis and management of Still’s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still’s disease. *Ann. Rheum. Dis.* 2024; 83:XXX-XXX. doi:10.1136/ard-2024-225851.
2. Vitale, A., et al. Still’s disease continuum from childhood to elderly: data from the international AIDA Network Still’s disease registry. *RMD Open* 2023; 9:e003578. doi:10.1136/rmdopen-2023-003578.
3. Bindoli, S., et al. Adult-onset Still’s disease (AOSD): advances in understanding pathophysiology, genetics and emerging treatment options. *Drugs* 2024; 84:257–274. doi:10.1007/s40265-024-01993-x.
4. Shen, et al. Personalized precision treatment for Still’s disease: molecular characteristics and disease progression. This innovative perspective potentially paves the way for tailored interventions, improving patient outcomes in the management of this complex rheumatological condition.
(Note: Specific page numbers for the first reference, as well as additional details for the fourth reference, need to be filled in where placeholders (XXX-XXX) are used. If more details are provided, I can refine the references further.)
